Vanguard Global Advisers
PRLD icon

Vanguard Global Advisers’s Prelude Therapeutics PRLD Stock Holding History

Vanguard Global Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.4K Buy
16,210
+11,574
+250% +$50.4K ﹤0.01% 2838
2026
Q1 		$15.9K Buy
+4,636
New +$12.2K ﹤0.01% 3383

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Global Advisers's PRLD Position: Q2 2026 in Review

Vanguard Global Advisers increased its Prelude Therapeutics (PRLD) stake by 250% in Q2 2026, buying an estimated $50.4K and bringing the position to 16,210 shares worth $86.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2838.

Vanguard Global Advisers first reported a position in PRLD in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Vanguard Global Advisers held 16,210 shares of Prelude Therapeutics worth $86.4K as of Q2 2026.
  • Vanguard Global Advisers bought 11,574 Prelude Therapeutics shares in Q2 2026, an estimated $50.4K.
  • Prelude Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2838 holding.
  • Vanguard Global Advisers first reported a position in Prelude Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.